MediciNova, Inc. (NASDAQ:MNOV - Get Free Report) shares passed above its two hundred day moving average during trading on Monday . The stock has a two hundred day moving average of $1.63 and traded as high as $2.12. MediciNova shares last traded at $2.11, with a volume of 16,257 shares changing hands.
Wall Street Analysts Forecast Growth
Several analysts recently issued reports on MNOV shares. D. Boral Capital started coverage on shares of MediciNova in a report on Monday, December 2nd. They issued a "buy" rating and a $9.00 price objective on the stock. StockNews.com initiated coverage on shares of MediciNova in a report on Tuesday. They issued a "hold" rating on the stock.
Check Out Our Latest Report on MNOV
MediciNova Stock Up 0.9 %
The firm has a market capitalization of $104.47 million, a price-to-earnings ratio of -10.05 and a beta of 0.84. The stock has a 50-day moving average price of $1.92 and a 200 day moving average price of $1.64.
Institutional Investors Weigh In On MediciNova
An institutional investor recently raised its position in MediciNova stock. Geode Capital Management LLC lifted its stake in shares of MediciNova, Inc. (NASDAQ:MNOV - Free Report) by 10.3% in the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 505,966 shares of the biopharmaceutical company's stock after purchasing an additional 47,201 shares during the quarter. Geode Capital Management LLC owned about 1.03% of MediciNova worth $1,063,000 at the end of the most recent quarter. 9.90% of the stock is owned by institutional investors.
MediciNova Company Profile
(
Get Free Report)
MediciNova, Inc, a biopharmaceutical company, focuses on developing novel and small molecule therapeutics for the treatment of serious diseases with unmet medical needs in the United States. It is developing MN-166 (ibudilast), an oral anti-inflammatory and neuroprotective agent for treating neurological and other disorders, such as primary and secondary progressive multiple sclerosis, amyotrophic lateral sclerosis, chemotherapy-induced peripheral neuropathy, degenerative cervical myelopathy, glioblastoma, and substance dependence and addiction, as well as prevention of acute respiratory distress syndrome, and long COVID.
See Also
Before you consider MediciNova, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and MediciNova wasn't on the list.
While MediciNova currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Like this article? Share it with a colleague.
Link copied to clipboard.
